Skip to main content
德源药业 logo

德源药业 — Investor Relations & Filings

Ticker · 920735 Beijing Stock Exchange Manufacturing
Open in API
Filings indexed 569 across all filing types
Latest filing 2023-07-30 AGM Information
Country CN China
Listing Beijing Stock Exchange 920735

About 德源药业

http://www.pharmdy.com

Deyuan Pharmaceutical specializes in the research, development, production, and commercialization of therapeutic drug preparations. The company focuses on chronic disease management, particularly in the fields of endocrinology and cardiovascular health. Its core product line includes treatments for diabetes, hypertension, and hyperlipidemia, featuring medications such as Metformin Hydrochloride sustained-release tablets, Pioglitazone Hydrochloride, and Valsartan. The organization emphasizes technological innovation and maintains rigorous quality control standards across its manufacturing processes. By leveraging advanced formulation technologies, the company develops high-efficacy pharmaceutical solutions aimed at addressing the long-term needs of patients with metabolic and circulatory disorders.

Recent filings

Filing Released Lang Actions
关于召开2023年第一次临时股东大会通知公告（提供网络投票）
AGM Information Classification · 95% confidence The document is a notice announcing the convening of the 2023 first extraordinary general meeting of shareholders (临时股东大会) for Jiangsu Deyuan Pharmaceutical Co., Ltd. It details the meeting date, voting methods, agenda items, registration procedures, and other logistical information. There is no financial data, earnings information, or detailed report content. The document is an announcement about a shareholders meeting rather than the meeting materials or results themselves. Therefore, it fits the category of AGM Information (AGM-R), which covers presentations and materials shared during or about the Annual or Extraordinary General Meeting. Given the document length and content, confidence is high.
2023-07-30 Chinese
开源证券股份有限公司关于江苏德源药业股份有限公司2021年限制性股票激励计划第二个解除限售期解除限售条件成就及回购注销部分限制性股票事项的核查意见
Regulatory Filings
2023-07-30 Chinese
独立董事关于第三届董事会第二十次会议相关事项的独立意见
Board/Management Information Classification · 95% confidence The document is an independent directors' opinion on matters discussed at a specific board meeting of Jiangsu Deyuan Pharmaceutical Co., Ltd. It includes detailed opinions on stock incentive plan conditions and stock repurchase and cancellation proposals. The content focuses on board-level decisions and independent directors' assessments rather than financial results, earnings, or regulatory filings. It is not a full annual or interim report, nor an earnings release or audit report. The document is not a simple announcement but a detailed opinion related to board matters. Therefore, it fits best under Board/Management Information (MANG), which covers announcements of changes or opinions related to the company's board or senior management activities.
2023-07-30 Chinese
关于2021年限制性股票激励计划第二个解除限售期解除限售条件成就的公告
Board/Management Information Classification · 95% confidence The document is a detailed announcement from Jiangsu Deyuan Pharmaceutical Co., Ltd. regarding the achievement of the second release period conditions for the 2021 restricted stock incentive plan. It includes extensive information about board and supervisory meetings, approvals, performance assessments, stock grant details, and stock repurchase and cancellation related to the incentive plan. The content focuses on corporate governance and management decisions related to stock incentives rather than financial results, earnings, or general regulatory filings. It is not a full annual or interim report, nor an earnings release or call transcript. The document is not a proxy solicitation or voting results announcement but rather a formal announcement about the status and conditions of a stock incentive plan and related board resolutions. This fits best under the category of Board/Management Information (MANG), which covers announcements of changes or decisions by the company's board or senior management, including stock incentive plans and related corporate governance matters. The document length (15,000 characters) and detailed content confirm it is not a brief announcement or a report publication notice. Therefore, the classification is MANG with high confidence.
2023-07-30 Chinese
关于与中国科学院上海药物研究所签订《技术开发合同》的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement by Jiangsu Deyuan Pharmaceutical Co., Ltd. regarding the signing of two technical development contracts with the Shanghai Institute of Materia Medica, Chinese Academy of Sciences. It details the contract terms, approval status, and the impact on the company. The document is relatively short (1759 characters) and focuses on a specific contract signing event rather than financial results or detailed financial data. There is no indication of financial statements, audit information, or regulatory certifications. It is not a report or presentation but an announcement of a corporate contract signing event. This fits best under the category of Regulatory Filings (RNS), which is the fallback for miscellaneous regulatory announcements that do not fit other categories.
2023-07-02 Chinese
关于与中国药科大学签订建立联合实验室合作协议书的公告
Regulatory Filings Classification · 95% confidence The document is an announcement by Jiangsu Deyuan Pharmaceutical Co., Ltd. about signing a cooperation agreement with China Pharmaceutical University to establish a joint laboratory. It details the contract terms, approval status, and the impact on the company. The document is short (1345 characters) and does not contain any financial statements, earnings data, or regulatory certifications. It is not a report but an announcement of a business cooperation agreement. There is no indication of board changes, financing, voting results, or other specific categories. This fits best under Regulatory Filings (RNS) as a general regulatory announcement that does not fit other categories.
2023-06-25 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.